Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, discusses data presented at the ESMO Virtual Congress 2020 from the Phase III ADAURA trial (NCT02511106), evaluating the use of osimertinib adjuvant therapy in patients with resected EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). Adjuvant treatment with osimertinib showed a significantly reduced incidence of CNS progression coupled with a large reduction in the distant relapse rate. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

свернуть